从更新的多学科欧洲MASLD指南中获取的关键信息
Paul Horn1,2, Frank Tacke1
1Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.
eGastroenterology
|June 13, 2025
概括
新的欧洲指南提供了与代谢功能障碍相关的脂肪性肝病 (MASLD) 的综合管理策略. 关键建议包括改变生活方式,治疗心脏代谢风险因素,以及用于代谢功能障碍相关的脂肪肝炎 (MASH) 的新疗法,如因克雷丁仿真药和resmetirom.
科学领域:
- 肝病学和胃肠道学
- 内分泌学和新陈代谢学
- 临床实践指南 临床实践指南
背景情况:
- 与代谢功能障碍相关的脂肪性肝病 (MASLD) 是一个日益严重的全球健康问题.
- 现有的管理策略需要更新,基于证据的临床实践指南.
- 欧洲肝脏,糖尿病和肥胖研究协会已经合作解决这一需求.
研究的目的:
- 为MASLD管理提出新的欧洲临床实践指南.
- 提供关于诊断,风险分层,监测,治疗和预防的详细建议.
- 纳入药理学和非侵入性诊断方法的最新进展.
主要方法:
- 三个主要的欧洲科学协会制定了指导方针.
- 审查和综合有关MASLD诊断和管理的当前证据.
- 包括对生活方式干预,心脏代谢风险因素管理和新药疗法的建议.
主要成果:
- 指南强调生活方式干预 (减肥,饮食,运动,戒酒) 是基本的.
- 胰岛素仿制剂 (塞马格卢提德,提泽帕提德) 显示出改善代谢功能障碍相关的脂肪肝炎 (MASH) 的前景.
- 新推包括用于查和纤维化检测的非侵入性测试 (NIT),以及用于MASH纤维化 (≥F2) 的resmetirom的潜在使用.
结论:
- 新的指导方针为MASLD管理提供了一个全面的框架.
- 建议采用多方面的方法,结合生活方式,风险因素控制和向治疗.
- 该指南强调了MASLD治疗的不断变化,包括新的药理选择和非侵入性监测工具.
相关概念视频
Diagnostic and Statistical Manual of Mental Disorders (DSM)
49
The Diagnostic and Statistical Manual of Mental Disorders (DSM) serves as the primary classification system for mental health disorders, providing standardized diagnostic criteria for clinicians and researchers. First published by the American Psychiatric Association (APA) in 1952, the DSM has undergone several revisions to reflect evolving psychiatric understanding. The fifth edition, DSM-5, released in 2013, introduced key updates that expanded diagnostic categories and modified diagnostic...
49
Chronic Pancreatitis II: Collaborative Care
77
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
77
Methods of Documentation VI: Case Management Model
564
The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic...
For example, a patient with a chronic...
564
Inflammatory Bowel Disease IV: Pharmacological Management
122
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
122


